Expansion of public funding for Lutathera in Ontario to now include pNETs patients

Luththera: Funding update for radionuclide therapy for pancreatic neoroendocrine tumours (pNETs).

Effective November 7, 2023, Ontario Health will fund the use of Lutathera to treat eligible pancreatic neuroendocrine tumour (pNETs) patients.  This is in addition to the existing mid-gut NETs indication and is aligned with pan-Canadian Oncology Drug Review (pCODR)Expert Review Committee (pERC) recommendations.